REGENXBIO (NASDAQ:RGNX) Insider Steve Pakola Sells 36,725 Shares of Stock

REGENXBIO Inc. (NASDAQ:RGNX) insider Steve Pakola sold 36,725 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $12.86, for a total value of $472,283.50. Following the transaction, the insider directly owned 213,009 shares in the company, valued at $2,739,295.74. This represents a 14.71% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Steve Pakola also recently made the following trade(s):

• On Monday, June 29th, Steve Pakola sold 19,608 shares of REGENXBIO stock. The stock was sold at an average price of $11.04, for a total value of $216,472.32.
• On Monday, May 11th, Steve Pakola sold 15,309 shares of REGENXBIO stock. The stock was sold at an average price of $11.02, for a total value of $168,705.18.

REGENXBIO Stock Performance

Shares of REGENXBIO stock opened at $13.09 on Thursday. REGENXBIO Inc. has a 52-week low of $5.45 and a 52-week high of $16.19. The stock’s 50-day simple moving average is $8.12 and its 200 day simple moving average is $9.91. The stock has a market capitalization of $676.73 million, a P/E ratio of -2.34 and a beta of 1.04.

REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Thursday, May 14th. The biotechnology company reported ($1.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.36). The business had revenue of $6.39 million for the quarter, compared to the consensus estimate of $25.84 million. REGENXBIO had a negative return on equity of 232.50% and a negative net margin of 330.23%. Equities research analysts forecast that REGENXBIO Inc. will post -3.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of RGNX. JPMorgan Chase & Co. lifted its position in REGENXBIO by 4.8% during the third quarter. JPMorgan Chase & Co. now owns 4,037,248 shares of the biotechnology company’s stock valued at $38,959,000 after purchasing an additional 185,223 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of REGENXBIO by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 3,374,140 shares of the biotechnology company’s stock worth $48,588,000 after buying an additional 36,042 shares during the last quarter. State Street Corp raised its position in shares of REGENXBIO by 15.2% during the 4th quarter. State Street Corp now owns 2,286,736 shares of the biotechnology company’s stock valued at $32,929,000 after buying an additional 301,858 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of REGENXBIO by 5.6% during the 4th quarter. AQR Capital Management LLC now owns 1,361,962 shares of the biotechnology company’s stock worth $19,612,000 after acquiring an additional 72,307 shares during the last quarter. Finally, Integral Health Asset Management LLC grew its position in REGENXBIO by 9.1% in the fourth quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the biotechnology company’s stock worth $17,280,000 after acquiring an additional 100,000 shares in the last quarter. 88.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on RGNX. Robert W. Baird lifted their price objective on shares of REGENXBIO from $27.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, June 22nd. Leerink Partners increased their target price on REGENXBIO from $17.00 to $18.00 and gave the stock an “outperform” rating in a research report on Monday, June 22nd. Morgan Stanley set a $16.00 price target on REGENXBIO in a report on Friday, May 15th. Barclays reduced their price target on REGENXBIO from $37.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, May 15th. Finally, Bank of America decreased their price objective on REGENXBIO from $25.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $23.82.

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.